SAN DIEGO, May 29, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases announced today it had been selected as a winner of Red Herring 's Top 100 North America award, a prestigious list honoring the year's most promising private technology ventures from the North American business region.
"We are proud to have been selected as a winner of this award and we are thankful to our devoted employees and investors for their enduring commitment to find a new treatment modality for patients with advanced heart failure." said Krisztina Zsebo Ph.D., President and CEO of Celladon Corporation.
"In 2013, selecting the Top 100 achievers was by no means a small feat" said Alex Vieux, publisher and CEO of Red Herring . "In fact, we had the toughest time in years because so many entrepreneurs have crossed significant milestones so early. But after much thought, rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across North America to the Top 100 Winners. We believe Celladon Corporation embodies the vision, drive and innovation that define a successful entrepreneurial venture. Celladon Corporation should be proud of its accomplishment, as the competition was very strong."
Red Herring 's editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation and intellectual property, management quality, business model, customer footprint, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers, al
|SOURCE Celladon Corporation|
Copyright©2012 PR Newswire.
All rights reserved